Walleye Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Walleye Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,500	Closed	-$410K	–	5302
2024 Q2	$410K	Buy	+1,500	New	+$436K	﹤0.01%	3677
2024 Q1	–	Sell	-1,281	Closed	-$421K	–	5429
2023 Q4	$414K	Buy	+1,281	New	+$402K	﹤0.01%	3098
2023 Q1	–	Sell	-3,330	Closed	-$1.4M	–	3942
2022 Q4	$1.4M	Sell	3,330 -7,564	-69%	-$3.05M	0.03%	780
2022 Q3	$4.54M	Buy	10,894 +8,233	+309%	+$4.1M	0.09%	249
2022 Q2	$1.32M	Sell	2,661 -5,983	-69%	-$3.12M	0.04%	513
2022 Q1	$4.87M	Buy	8,644 +7,600	+728%	+$4.58M	0.13%	168
2021 Q4	$789K	Buy	1,044 +280	+37%	+$210K	0.02%	722
2021 Q3	$570K	Buy	+764	New	+$572K	0.02%	730
2019 Q4	–	Sell	-10	Closed	-$3.52K	–	1798
2019 Q3	$3K	Sell	10 -20	-67%	-$6.52K	﹤0.01%	1821
2019 Q2	$9K	Buy	+30	New	+$8.98K	﹤0.01%	1595

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Walleye Capital's BIO Position: Q3 2024 in Review

Walleye Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 1,500 shares — an estimated $410K sold.

Walleye Capital first reported a position in BIO in Q2 2019 and held it in 10 quarters. The position peaked at $4.87M in Q1 2022. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

Walleye Capital reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
Walleye Capital sold 1,500 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $410K.
Walleye Capital first reported a position in Bio-Rad Laboratories Class A in Q2 2019 and held it in 10 quarters.
Walleye Capital's Bio-Rad Laboratories Class A position peaked at $4.87M in Q1 2022.
438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.